Last reviewed · How we verify
NCT05908838
Clinical Study of Modified Banxia Xiexin Decoction Treatment on Gastric Cancer
EARLY_PHASE1 trial testing Modified Banxia Xiexin Decoction in Gastric Cancer (Diagnosis) in 146 participants. Completed in 2 December 2022.
1 December 2022
Quick facts
| Lead sponsor | ShuGuang Hospital |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 146 |
| Start date | 1 January 2017 |
| Primary completion | 1 December 2022 |
| Estimated completion | 2 December 2022 |
Drugs / interventions tested
- Modified Banxia Xiexin Decoction — full drug profile →
- combination chemotherapy with Placebo granules — full drug profile →
Conditions studied
- Gastric Cancer (Diagnosis) — all drugs for Gastric Cancer (Diagnosis) →
Sponsor
ShuGuang Hospital
Who can join
Adults 17 to 75, any sex, with Gastric Cancer (Diagnosis). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Research purpose To elucidate the effect mechanism and clinical effective of Modified Banxia Xiexin Decoction in the prevention and treatment of gastric cancer. From genes related to cell differentiation, proliferation, apoptosis, tumor invasion and metastasis, genes related to immune inflammation and immune escape and other possible aspects to elucidate the effective and mechanism of Modified Banxia Xiexin Decoction's treatment on gastric cancer
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05908838
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastric Cancer (Diagnosis)
Currently open trials in the same condition.
- NCT07401173 — DeepComp for Prediction of Gastric Cancer Postoperative Complications (DeepComp-Prospective) · recruiting
- NCT07307560 — High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients · NA · recruiting
- NCT07481110 — Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Gastric Cancers in Algeria · recruiting
- NCT07517432 — The UGIRA International Registry for RAMIG for Gastric Cancer · recruiting
Other ShuGuang Hospital trials
Trials by the same sponsor.
- NCT07320937 — Effects of Yiqi Fuyuan Paste Formula in Chronic Fatigue Syndrome: A Randomized Double-Blind Controlled Clinical Trial. · NA · enrolling by invitation
- NCT04641819 — Yangzheng Compound Mixture in the Treatment of Sleep Disorder in Cancer Patients · Phase 4 · active not recruiting
- NCT04279197 — Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu · Phase 2 · completed
- NCT04645407 — Effects of Fuzheng Huayu Tablets on COVID-19 · Phase 4 · completed
- NCT04200781 — Clinical Evaluation of Shengdi Dahuang Decoction in the Treatment of Acute Hemorrhagic Stroke · Phase 4 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05908838 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ShuGuang Hospital
- Last refreshed: 18 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05908838.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing